Tenaya Therapeutics(TNYA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Established $45 Million Credit Facility with Silicon Valley Bank to Provide Financial Flexibility Ahead of Multiple Potential Miles ...